Skip to main content
. Author manuscript; available in PMC: 2023 Jun 14.
Published in final edited form as: Nat Med. 2022 Nov 10;28(11):2293–2300. doi: 10.1038/s41591-022-02055-z

Extended Data Fig. 4. Validation of the clinical and clinical + protein models for IGT (a) and iIGT (b) in the independent WHII study.

Extended Data Fig. 4

The clinical + protein model significantly outperformed the clinical model (p-valueIGT = 5.26 × 10−5; p-valueiIGT = 1.5 × 10−17). The improvement was of similar magnitude than that observed in the Fenland study, although with overall lower AUROCs (clinical models: AUROCIGT = 0.66 (0.64–0.69), and AUROCiIGT = 0.60 (0.57–0.62); clinical + protein models: AUROCIGT = 0.70 (0.68–0.72) and AUROCiIGT = 0.69 (0.67–0.71)). Significant differences between the AUROCs were asses by the Delong method. This might be best explained by differences in the characteristics of the study population, the design and the lack of HbA1c to define iIGT (see Methods).